86 related articles for article (PubMed ID: 2225560)
1. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial.
Walker RG; Yu SH; Owen JE; Kincaid-Smith P
Clin Nephrol; 1990 Sep; 34(3):103-7. PubMed ID: 2225560
[TBL] [Abstract][Full Text] [Related]
2. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis.
Woo KT; Edmondson RP; Yap HK; Wu AY; Chiang GS; Lee EJ; Pwee HS; Lim CH
Clin Nephrol; 1987 Feb; 27(2):56-64. PubMed ID: 3549083
[TBL] [Abstract][Full Text] [Related]
3. Effects of triple therapy in IgA nephritis: a follow-up study 5 years later.
Woo KT; Lee GS; Lau YK; Chiang GS; Lim CH
Clin Nephrol; 1991 Aug; 36(2):60-6. PubMed ID: 1934661
[TBL] [Abstract][Full Text] [Related]
4. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin.
Woo KT; Lee GS
Clin Nephrol; 1991 Apr; 35(4):184. PubMed ID: 1855324
[No Abstract] [Full Text] [Related]
5. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial.
Yoshikawa N; Honda M; Iijima K; Awazu M; Hattori S; Nakanishi K; Ito H;
Clin J Am Soc Nephrol; 2006 May; 1(3):511-7. PubMed ID: 17699253
[TBL] [Abstract][Full Text] [Related]
6. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial.
Bennett WM; Walker RG; Kincaid-Smith P
Clin Nephrol; 1989 Mar; 31(3):128-31. PubMed ID: 2539929
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis.
Murphy BF; McDonald I; Fairley KF; Kincaid-Smith PS
Clin Nephrol; 1992 May; 37(5):229-34. PubMed ID: 1606772
[TBL] [Abstract][Full Text] [Related]
8. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment.
McIntyre CW; Fluck RJ; Lambie SH
Clin Nephrol; 2001 Sep; 56(3):193-8. PubMed ID: 11597033
[TBL] [Abstract][Full Text] [Related]
9. Combined therapy in children and adolescents with IgA nephropathy.
Murakami K; Yoshioka K; Akano N; Takemura T; Okada M; Aya N; Hino S; Miyazato H; Yagi K; Maki S
Nihon Jinzo Gakkai Shi; 1994 Jan; 36(1):38-43. PubMed ID: 8107307
[TBL] [Abstract][Full Text] [Related]
10. Benefit of cyclophosphamide therapy in IgA nephritis may have been obscured by warfarin-related nephropathy in the randomized trials in which warfarin and dipyridamole were used in combination with cyclophosphamide.
Brodsky SV; Rovin BH; Hebert LA
Nephrol Dial Transplant; 2012 Feb; 27(2):475-7. PubMed ID: 21948859
[No Abstract] [Full Text] [Related]
11. Combination therapy using prednisolone and cyclophosphamide slows the progression of moderately advanced IgA nephropathy.
Tsuruya K; Harada A; Hirakata H; Mitsuiki K; Johko T; Kondoh H; Takechi S; Fujishima M
Clin Nephrol; 2000 Jan; 53(1):1-9. PubMed ID: 10661476
[TBL] [Abstract][Full Text] [Related]
12. The effect of treatment with prednisolone or cyclophosphamide-warfarin-dipyridamole combination on the outcome of patients with membranous nephropathy.
Shearman JD; Yin ZG; Aarons I; Smith PS; Woodroffe AJ; Clarkson AR
Clin Nephrol; 1988 Dec; 30(6):320-9. PubMed ID: 3243041
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function.
Moriyama T; Honda K; Nitta K; Yumura W; Nihei H
Clin Exp Nephrol; 2004 Sep; 8(3):237-42. PubMed ID: 15480901
[TBL] [Abstract][Full Text] [Related]
14. A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: preliminary trial.
Kanno Y; Witt M; Okada H; Nemoto H; Sugahara S; Nakamoto H; Suzuki H
Clin Exp Nephrol; 2003 Mar; 7(1):48-51. PubMed ID: 14586743
[TBL] [Abstract][Full Text] [Related]
15. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
[TBL] [Abstract][Full Text] [Related]
16. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
[TBL] [Abstract][Full Text] [Related]
17. Follow-up renal biopsies in IgA nephritic patients on triple therapy.
Woo KT; Chiang GS; Lim CH
Clin Nephrol; 1987 Dec; 28(6):304-5. PubMed ID: 3442958
[No Abstract] [Full Text] [Related]
18. Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy.
Parinyasiri U; Ong-Ajyooth L; Parichatikanond P; Ong-Ajyooth S; Liammongkolkul S; Kanyog S
J Med Assoc Thai; 2004 Feb; 87(2):143-9. PubMed ID: 15061297
[TBL] [Abstract][Full Text] [Related]
19. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
Branten AJ; Wetzels JF
Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
[TBL] [Abstract][Full Text] [Related]
20. [A prospective controlled study of sairei-to in childhood IgA nephropathy with focal/minimal mesangial proliferation. Japanese Pediatric IgA Nephropathy Treatment Study Group].
Yoshikawa N; Ito H; Sakai T; Takekoshi Y; Honda M; Awazu M; Ito K; Iitaka K; Koitabashi Y; Yamaoka K; Nakagawa K; Nakamura H; Matsuyama S; Seino Y; Takeda N; Hattori S; Ninomiya M
Nihon Jinzo Gakkai Shi; 1997 Jul; 39(5):503-6. PubMed ID: 9283216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
